Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gimatecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 19/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | GLA | P06280 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | STAT6 | P42226 | 1/20 | 0.62 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.62 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | HNRNPA1 | P09651 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gimatecan SCHEMBL24685122 | 1.00 | TOP1 (0.79) | TOP1ALDH1A1GLAMEN1KMT2A | |
| Gimatecan SCHEMBL15341182 | 1.00 | TOP1 (0.79) | TOP1ALDH1A1GLAMEN1KMT2A | |
| Gimatecan SCHEMBL1649254 | 1.00 | TOP1 (0.79) | TOP1ALDH1A1GLAMEN1KMT2A | |
| Gimatecan SCHEMBL27721325 | 1.00 | TOP1 (0.79) | TOP1ALDH1A1GLAMEN1KMT2A | |
| Gimatecan SCHEMBL29358288 | 1.00 | TOP1 (0.79) | TOP1ALDH1A1GLAMEN1KMT2A | |
| SCHEMBL3181051 | 0.93 | TOP1 (0.76) | TOP1ALDH1A1GLAMEN1KMT2A | |
| SCHEMBL25932531 | 0.92 | TOP1 (0.68) | TOP1ALDH1A1GLAMEN1KMT2A | |
| SCHEMBL22843988 | 0.92 | TOP1 (0.81) | TOP1ALDH1A1GLAMEN1KMT2A | |
| SCHEMBL2028767 | 0.92 | TOP1 (0.81) | TOP1ALDH1A1GLAMEN1KMT2A | |
| SCHEMBL2028388 | 0.92 | TOP1 (0.85) | TOP1ALDH1A1GLAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814520-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A CAMTOTHECIN DERIVATE | SIGMA TAU IND FARMACEUTI (IT) | 2016-04-13 | — | — | EP | claimed |
| EP-1759699-B1 | LIPOSOME PREPARATION CONTAINING SLIGHTLY WATER-SOLUBLE CAMPTOTHECIN | YAKULT HONSHA KK (JP) | 2016-01-20 | — | — | EP | claimed |
| US-8975248-B2 | Combinations of therapeutic agents for treating cancer | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2015-03-10 | — | — | US | claimed |
| US-8518961-B2 | spontaneously dispersible; 7-t-butoxyiminomethylcamptothecin in microemulsion preconcentrate; topoisomerase I inhibitor; proliferative diseases including cancer; stability; bioavailability | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2013-08-27 | — | — | US | claimed |
| EP-1915153-B1 | IMMEDIATE RELEASE THERAPEUTIC SYSTEMS FOR IMPROVED ORAL ABSORPTION OF 7-[(E)-TERT-BUTYLOXYIMINOMETHYL]CAMTOTHECIN | SIGMA TAU IND FARMACEUTI (IT) | 2013-04-10 | — | — | EP | claimed |
| EP-2515898-A1 | ANTICANCER COMBINATION OF ARTEMISININ-BASED DRUGS AND OTHER CHEMOTHERAPEUTIC AGENTS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2012-10-31 | — | — | EP | claimed |
| EP-1828196-B1 | STEREOSELECTIVE PROCESS AND CRYSTALLINE FORMS OF A CAMPTOTHECIN | SIGMA TAU IND FARMACEUTI (IT) | 2012-10-17 | — | — | EP | claimed |
| US-20120258181-A1 | ANTICANCER COMBINATION OF ARTEMISININ-BASED DRUGS AND OTHER CHEMOTHERAPEUTIC AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2012-10-11 | — | — | US | claimed |
| US-20120093809-A1 | USE OF ALKANOYL L-CARNITINE IN COMBINATION WITH CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF NEOPLASMS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2012-04-19 | — | — | US | claimed |
| US-8124769-B2 | Stereoselective process and crystalline forms of a camptothecin | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2012-02-28 | — | — | US | claimed |
| WO-2006065780-A2 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2006-06-22 | — | — | WO | claimed |
| WO-2006053755-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A CAMTOTHECIN DERIVATE | NOVARTIS AG (CH) | 2006-05-26 | — | — | WO | claimed |
| WO-2005120643-A2 | USE OF 7-T-BUTOXYIMINOMETHYLCAMPTOTHECIN FOR TREATING UTERINE NEOPLASMS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2005-12-22 | — | — | WO | claimed |
| WO-2005110486-A2 | 7-T-BUTOXYIMINOMETHYLCAMPTOTHECIN CONJUGATED IN POSITION 20 WITH INTEGRIN ANTAGONISTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2005-11-24 | — | — | WO | claimed |
| US-20040018988-A1 | Camptothecin derivatives having antitumor activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-01-29 | — | — | US | claimed |
| EP-1044977-B1 | Camptothecin derivatives having antitumor activity | SIGMA TAU IND FARMACEUTI (IT) | 2002-05-02 | — | — | EP | claimed |
| US-20010008939-A1 | Camptothecin derivatives having antitumor activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.. | 2001-07-19 | — | — | US | claimed |
| US-6242457-B1 | OXIME DERIVATIVES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2001-06-05 | — | — | US | claimed |
| EP-1044977-A1 | Camptothecin derivatives having antitumor activity | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2000-10-18 | — | — | EP | claimed |
| WO-2000053607-A1 | CAMPTOTHECIN DERIVATIVES HAVING ANTITUMOR ACTIVITY | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-09-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008939-A1 | Camptothecin derivatives having antitumor activity | TOP1, TOP2A, TYMP | TOP1 1/4885ALDH1A1 2202/4885GLA 1623/4885 |
| US-20040018988-A1 | Camptothecin derivatives having antitumor activity | TOP1, TOP2A, TOP2B | TOP1 1/4885ALDH1A1 1248/4885GLA 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.